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Physiotherapy andOccupational Therapy vs No Therapy
inMild toModerate Parkinson Disease
A Randomized Clinical Trial
Carl E. Clarke, MD; Smitaa Patel, MSc; Natalie Ives, MSc; Caroline E. Rick, PhD; Francis Dowling, BSc;
RebeccaWoolley, MSc; KeithWheatley, DPhil; Marion F. Walker, PhD; Catherine M. Sackley, PhD;
for the PD REHAB Collaborative Group
IMPORTANCE It is unclear whether physiotherapy and occupational therapy are clinically
effective and cost-effective in Parkinson disease (PD).
OBJECTIVE To perform a large pragmatic randomized clinical trial to evaluate the clinical
effectiveness of individualized physiotherapy and occupational therapy in PD.
DESIGN, SETTING, AND PARTICIPANTS The PD REHAB Trial was amulticenter, open-label,
parallel group, controlled efficacy trial. A total of 762 patients with mild to moderate PDwere
recruited from 38 sites across the United Kingdom. Recruitment took place between October
2009 and June 2012, with 15 months of follow-up.
INTERVENTIONS Participants with limitations in activities of daily living (ADL) were
randomized to physiotherapy and occupational therapy or no therapy.
MAIN OUTCOMES ANDMEASURES The primary outcomewas the Nottingham Extended
Activities of Daily Living (NEADL) Scale score at 3 months after randomization. Secondary
outcomes were health-related quality of life (assessed by Parkinson Disease
Questionnaire–39 and EuroQol-5D); adverse events; and caregiver quality of life. Outcomes
were assessed before trial entry and then 3, 9, and 15 months after randomization.
RESULTS Of the 762 patients included in the study (mean [SD] age, 70 [9.1] years), 381
received physiotherapy and occupational therapy and 381 received no therapy. At 3 months,
there was no difference between groups in NEADL total score (difference, 0.5 points; 95% CI,
−0.7 to 1.7; P = .41) or Parkinson Disease Questionnaire–39 summary index (0.007 points;
95% CI, −1.5 to 1.5; P = .99). The EuroQol-5D quotient was of borderline significance in favor
of therapy (−0.03; 95% CI, −0.07 to −0.002; P = .04). Themedian therapist contact time was
4 visits of 58minutes over 8 weeks. Repeated-measures analysis showed no difference in
NEADL total score, but Parkinson Disease Questionnaire–39 summary index (diverging 1.6
points per annum; 95% CI, 0.47 to 2.62; P = .005) and EuroQol-5D score (0.02; 95% CI,
0.00007 to 0.03; P = .04) showed small differences in favor of therapy. There was no
difference in adverse events.
CONCLUSIONS AND RELEVANCE Physiotherapy and occupational therapy were not associated
with immediate or medium-term clinically meaningful improvements in ADL or quality of life
in mild to moderate PD. This evidence does not support the use of low-dose,
patient-centered, goal-directed physiotherapy and occupational therapy in patients in the
early stages of PD. Future research should explore the development and testing of more
structured and intensive physical and occupational therapy programs in patients with all
stages of PD.
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P arkinson disease (PD) causes problems with activitiesof daily living (ADL) that are only partially treated bymedication and occasionally surgery. Despite treat-
ment, patients go on to develop intractable motor problems,
including falls, with mental health problems and other non-
motorsymptoms.Physiotherapy(PT)andoccupational therapy
(OT) are traditionally used later in the disease.1 However, ser-
viceprovisionvarieswidely,withsomecenters involvingphys-
iotherapists andoccupational therapists fromdiagnosis,while
other areas have no specialist services.
Cochrane reviews of PT for PD found small but signifi-
cant effects onmotor function but not quality of life (QoL).2,3
A Cochrane review of OT found insufficient evidence of
effectiveness.4 Previous trialswith both therapieswere small
with short-termfollow-up.2-4Despite this lackof evidence, the
UKNational Institute forHealth andCareEffectiveness guide-
lines, although recognizing these shortcomings and recom-
mending further trials, stated that all patients shouldhave ac-
cess to both therapies.1
The PDREHABTrialwas designed to evaluate the clinical
effectiveness and cost-effectiveness of individualizedPT and
OT in patientswith PD. The current trial designwas informed
by our pilot study of OT in PD.5
Methods
The PD REHAB Trial was a large-scale pragmatic, multi-
center, randomized clinical trial to evaluate the effects of in-
dividualized PT and OT on ADL and QoL in patients with PD.
The full trial protocol can be found in Supplement 1.
Study Participants
Recruitment tookplacebetweenOctober2009andJune2012.
Patients from 38 neurology or geriatric medicine outpatient
centers across the United Kingdomwere invited to take part.
Eligibility criteria were idiopathic PD defined by UK Parkin-
son Disease Society Brain Bank Criteria6; self- or caregiver-
reported limitations in ADL; and the investigator was uncer-
tain that the patientwould require PT and/orOTduring the 15
months of the trial (ie, equipoise about the need for therapy
existed). Exclusion criteria were dementia as locally defined
and receipt of PT or OT for PD in the last 12 months. All pa-
tients gave written informed consent before randomization.
Ethical approval was granted by theWest Midlands Research
EthicsCommitteeand local approvalwasobtainedat eachpar-
ticipating center.
Randomization and Therapy Allocation
Patientswere randomized (1:1) between combined PT andOT
(therapies group) or no therapy (control group) using an on-
line randomization service at the University of Birmingham
Clinical Trials Unit. Randomization used a computer-based
algorithm with minimization by baseline Nottingham Ex-
tendedActivitiesofDailyLiving (NEADL)Scale total score (limi-
tations in ADL: severe, 0-21; moderate, 22-43; and mild 44-
66), Hoehn andYahr (H&Y) stage7 (≤2; 2.5; 3; and ≥4), and age
(<60; 60-69; 70-79; and ≥80 years).
Intervention
PhysiotherapyandOTweredelivered in thecommunityand/or
outpatient setting by qualified therapists working within the
National Health Service (NHS) per local practice. Before the
trial, a framework for therapy content was developed and
agreed on by expert therapist groups based on previouswork
on standards of NHS PT and OT and European guidelines.8-11
This framework was based on usual NHS practice and not an
innovative intervention.Following initial assessmentsbyboth
therapists, therapy was tailored to an individual patient’s re-
quirements using a patient-centered joint goal-setting ap-
proach. Interactionsbetween therapists andpatientswerede-
scribed and quantified using predefined recording forms and
included administration time (eg, ordering equipment). Con-
trolpatients consented tohave therapiesdeferreduntil theend
of the 15-month trial, unless pressing reasons for therapy de-
veloped. Because therapies may have been arranged outside
the trial, control patients were asked whether they had re-
ceived any therapy at each assessment point.
Primary OutcomeMeasure
Total NEADL score at 3 months after randomization was the
primary outcome measure.12 The NEADL measures instru-
mentalADL,whicharespecificallyaddressedbyPTandOTand
includes more complex ADL issues such as making a meal,
cleaning, and traveling on public transport. The NEADL scale
was developed for stroke but is used widely as a generic out-
comemeasure in rehabilitation trials of older people. It is sen-
sitive to change inOT trials13 andwas successfully used in our
pilot study of OT for PD, with good correlation with the Uni-
fied Parkinson Disease Rating Scale and the Parkinson Dis-
ease Questionnaire–39 (PDQ-39) ADL domains.5
Secondaryoutcomemeasureswerepatient-ratedQoLusing
the39-itemPDQ,14consistingof8domainsandthemostwidely
used disease-specific QoL rating scale for PD, and EuroQol-5D
(EQ-5D, 3-level version), a generic QoL scale; adverse events;
andcaregiverwell-beingusingShortForm–12 (SF-12,version2).
Followingariskassessment,onlytherapy-relatedadverseevents
andserious adverseeventswere recorded.Theseweredefined
as falls or equipment failure leading to injury requiring a hos-
pital, general practitioner, or ambulance visit or to death. A
healtheconomicsanalysiswasconductedalongsidePDREHAB
and will be reported separately. Outcomes were collected in
person at baseline before randomization, then by mail at 3, 9,
Key Points
Question: Are physiotherapy and occupational therapy clinically
effective in Parkinson disease?
Findings: In this randomized clinical trial in 762 patients with mild
to moderate Parkinson disease, physiotherapy and
occupational therapy were not associated with immediate or
medium-term clinically meaningful improvements in activities of
daily living or quality of life.
Meaning: This study shows that more structured and intensive
physical and occupational therapy programs should be developed
and tested at all stages of Parkinson disease.
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and 15monthsafter randomization.Antiparkinsonianmedica-
tiondosagewasconverted into levodopadoseequivalentsusing
a standard formula.15
Statistical Analysis
Aminimally clinically important change inNEADLscore inpa-
tients with stroke is 1 to 2 points.16 However, such a small
change may be of little benefit to patients; a clinically mean-
ingful change in NEADL for patients is likely to be around
double this at 2.5points.A2-point change inNEADLscore rep-
resentsbecoming independent in 1 item(eg, stair climbingand
crossing roads) or improvement in 2 items (eg, being depen-
dent on another person with help to being fully indepen-
dent). To detect a 2.5-point difference in NEADL at 3 months
(using theobservedSDfromthePDOTpilot trial5of 10.1points;
P = .05, 2-tailed; 90% power) required 340 patients in each
group: this increased to 750participants (375 per group) to al-
low for around 10% noncompliance and drop out.
Figure 1. CONSORTDiagram for PD REHAB Trial
762 Randomized
381 Allocated to PT/OTa
353 Started PT/OT within 3 mo 
of randomization (93%)
25 Did not receive PT/OT within 3 mo
of randomization (6%)c
12 Started PT/OT after 3 mo
13 Never received PT/OT
3 Unknown whether patient received
PT/OT because therapy logs
not returned (1%)
350 With 3-mo NEADL data available
for analysis (/381; 92%) 
23 Form expected but not returned
8 Form not expected
2 Withdrawn
5 Partially withdrawne
1 Died of respiratory illness
311 With 15-mo NEADL data available
for analysis (/367; 85%) 
45 Form expected but not returned
11 Form not expected
3 Withdrawn
4 Partially withdrawne
4 Died of cancer, cardiovascular illness,
respiratory illness, and falls/fracture
326 With 9-mo NEADL data available
for analysis (/373; 87%) 
41 Form expected but not returned
6 Form not expected
3 Partially withdrawne
3 Died of cancer, respiratory illness,
and road traffic crash
381 Allocated to no therapyb
372 Received no therapy within 3 mo
of randomization (98%)
9 Crossed over to PT/OT within 3 mo
of randomization (2%)d
Reasons for crossover included
worsening PD symptoms, falls,
and balance problems
349 With 3-mo NEADL data available
for analysis (/381; 92%) 
27 Form expected but not returned
5 Form not expected
2 Withdrawn
1 Partially withdrawne
2 Died of cardiovascular illness and
natural causes
322 With 15-mo NEADL data available
for analysis (/364; 88%) 
36 Form expected but not returned
6 Form not expected
2 Partially withdrawne
4 Died of cancer, cardiovascular illness,
and respiratory illness
331 With 9-mo NEADL data available
for analysis (/376; 88%) 
33 Form expected but not returned
12 Form not expected
1 Withdrawn
9 Died of cancer, cardiovascular illness,
respiratory illness, and infection
2 Partially withdrawne
Patient recruitment and follow-up. Numbers of patients assessed for eligibility
and excluded are not included in the flow diagram because screening logs are
not available for this trial, so these data cannot be provided. NEADL indicates
Nottingham Extended Activities of Daily Living; OT, occupational therapy;
PT, physical therapy; PD, Parkinson disease.
a Eight patients randomized to the PT and OT group were later found to be
ineligible because they had received PT and/or OT for PD in the 12 months
prior to randomization (exclusion criteria). One patient did not receive any PT
or OT after randomization (crossover; only baseline data available: diagnosed
as having cancer and died at 5 months after randomization). One patient did
not receive PT or OTwithin 3months but was referred for PT outside of the
trial at 6months (3-, 9-, and 15-month data available). The other 6 patients all
received PT and/or OT after randomization (baseline and 3-month data
available except for 1 patient, where only baseline data were available).
b Three patients randomized to the no therapy group were subsequently found
to be ineligible because they had received PT and/or OT for PD in the 12
months prior to randomization (exclusion criteria). One patient received PT
and/or OT within 3months of randomization (crossover). For all 3 patients,
baseline and 3-month data were available.
c Thirteen patients randomized to the PT and OT group are known to have not
received any PT or OT. Baseline and 3-month data are available for 2 of these
patients (for the other 11 patients, only baseline data are available). Twelve
patients did not receive PT or OT by 3months after randomization but did
start therapy after 3 months; baseline and 3-month data are available for all
patients (except 2, 1 of whom had baseline data only and 1 who had 3-month
data only).
dNine patients randomized to no therapy had some PT and/or OT before their
3-month NEADL formwas completed; all patients had baseline and 3-month
data available.
e Partially withdrawn patients did not want to complete patient forms but
agreed to clinical follow-up.
Physiotherapy and Occupational Therapy vs No Therapy in Parkinson Disease Original Investigation Research
jamaneurology.com (Reprinted) JAMANeurology March 2016 Volume 73, Number 3 293
Downloaded From: http://jamanetwork.com/ by a University of Nottingham User  on 10/26/2016
Copyright 2016 American Medical Association. All rights reserved.
TheprimaryanalysiswaschangeinNEADLtotalscore inthe
therapiesgroupbetweenbaselineandthe3-monthassessment
compared with that in the no therapy group. An independent
2-sample t testwasused to compare changesbetweenbaseline
and3months in theNEADLscorebetweenthe2groups.Results
arepresentedasmeandifferencebetweengroupswith95%CIs.
This analysiswas repeated for individual NEADLdomains and
secondary outcome measures. The medium-term effect or
whetheranybenefitof treatmentpersistedbeyondthe initial in-
terventionperiodwasevaluatedat9and15monthsafterrandom-
ization, using both t tests at each point and a mixed-model
repeated-measures analysis across all points for all outcomes.
Analyses were performed on an intention-to-treat basis.
Missingdata in PDQ-39domain scoreswere imputedusing an
expectation maximization algorithm.17,18 There is no estab-
lished imputationmethod for theNEADLscale; therefore, pri-
maryanalysesusedavailabledataonly,withno imputation for
missing values. However, sensitivity analyses using a best
(score, 3), worst (score, 0),middle (score, 1.5), and average (at
participant level) case score for missing items on the NEADL
were explored. Three apriori subgroup analyses used a test of
interaction to explore the effect of the therapies at 3 months
at different levels of ADL, disease stage, and age. All sub-
group analyses were interpreted cautiously.
Analyseswere performed using SAS version 9.2 (SAS Insti-
tute). Interimanalysesofunblindedefficacyandsafetydatawere
reviewedannuallybyan independentdatamonitoringcommit-
tee,whichreportedtoanindependentTrialSteeringCommittee.
Results
Study Population
A total of 762 people with PDwere randomized to either com-
bined PT andOT or no therapy (381 per group; Figure 1). Base-
line characteristicswere similar between groups (Table 1). The
meanagewas70years,65%weremale, andthemediandisease
durationwas3.1years (mean,4.6years).Mostpatientshadmild
tomoderatedisease,with67%inH&Ystage2orless(254patients
in each group) andmedianNEADL total score of 54 (mean, 51).
At3months,92%ofpatients (350 in thePT/OTarmand349
in the no therapy arm) in each arm had completed the NEADL
(Figure 1). By 15months, 311 (82%of 381 patients randomized)
in the therapies armhadcompleted theNEADLcomparedwith
322 (85%of 381 patients randomized) in the control arm.
Twenty-five patients (6%) allocated to the therapies arm
did not receive therapy by 3 months after randomization (12
startedPTand/orOTafter 3months and 13never received any
therapy; Figure 1). Nine patients (2%) allocated to no therapy
received therapy for PD-related problems within 3 months,
mainly owing to worsening PD symptoms including falls and
imbalance (Figure 1).
Therapy Content
In the therapies group, the median number of therapy ses-
sions was 4 (range, 1-21), with a mean time per session of 58
minutes.Themeandurationof therapywas8weeks.Themean
total dose of both therapies was 263 minutes (range, 38-1198
Table 1. Demographics and Baseline Characteristics
Characteristic PT/OT No Therapy
No. of patients randomized 381 381
Demographics
Age, mean (SD) [range], ya 70 (9.1) [35-90] 70 (9.3) [35-91]
Age category, No. (%), y
<60 47 (12) 46 (12)
60-69 129 (34) 129 (34)
70-79 148 (39) 151 (40)
≥80 57 (15) 55 (14)
Male, No. (%) 240 (63) 258 (68)
BMI
No. 327 333
Mean (SD) 27.2 (5.4) 26.9 (4.4)
Range 16.5-54.9 16.8-44.0
Stage of PD
Duration of PD, y
No. 381 379
Mean (SD) 4.5 (4.9) 4.6 (4.5)
Range 0.01-29.9 0-25.6
Median (IQR) 3.0 (1.0-6.1) 3.3 (1.3-6.4)
Hoehn & Yahr stage, No. (%)a
≤2.0 254 (67) 254 (67)
2.5 46 (12) 46 (12)
3.0 61 (16) 61 (16)
≥4.0 20 (5) 20 (5)
Drug dose
Levodopa equivalent dose, mg/d
No. 381 381
Mean (SD) [range] 453 (357.9) 498 (372.8)
Range 0-1877 0-2181
NEADL Scaleb
Total score
No. 381 381
Mean (SD) [range] 51 (12.9) 51 (13.3)
Range 6-66 8-66
Median (IQR) 53 (43-61) 54 (42-62)
NEADL total score category,
No. (%)a
0-21 (severe) 14 (4) 14 (4)
22-43 (moderate) 88 (23) 88 (23)
44-66 (mild) 279 (73) 279 (73)
PDQ-39c
Summary index
No. 380 377
Mean (SD) [range] 23.8 (14.5) 23.7 (14.4)
Range 2.4-78.4 1.9-67.4
Median (IQR) 22.4 (12.6-32.3) 21.1 (12.2-33.0)
Abbreviations: BMI, bodymass index (calculated as weight in kilograms divided
by height in meters squared); IQR, interquartile range; NEADL, Nottingham
Extended Activities of Daily Living; OT, occupational therapy; PD, Parkinson
disease; PDQ-39, Parkinson Disease Questionnaire–39; PT, physical therapy.
a Age, Hoehn & Yahr stage, and NEADL total score wereminimization variables
in the randomization algorithm.
bTotal score ranges from0 to 66, where higher scores are better.
c Summary index ranges from0 to 100, where lower scores are better.
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minutes).Most PTwasperformed inoutpatient settings (53%)
rather thanthecommunity (39%)orothersetting (8%),whereas
OT was more commonly performed in the community (69%)
rather than outpatient (29%) or other (2%) settings.
Physiotherapylogsshowedthemost frequent interventions
were for gait (96%ofpatients;n = 330), posture (93%;n = 319),
balance(90%;n = 310),physicalconditioning(81%;n = 280),and
transfers (79%;n = 271).Occupational therapy logs showedthe
most frequent interventionswere for transfers (46%; n = 150),
dressing and grooming (37%; n = 122), sleep and fatigue (32%;
n = 105), indoormobility (29%;n = 96), household tasks (29%;
n = 95), and other environmental issues (28%; n = 93).
Validation of therapy logs was undertaken by comparing
logs with full-text therapy notes for 38 patients chosen at
random from 10 geographically diverse centers. Interven-
tionsweregrouped into the following:assessment,equipment/
adaptation prescription, exercise recommendations, referral
to other specialists, and “other advice.” Physiotherapists
prescribed a range of exercise programs tailored to their
assessment of patient mobility and activity levels. Only 3
Table 2. Patient Activities of Daily Living andQuality of Life Scores at 3Months
Variable
Mean (SD)
Mean Difference
(95% CI)a P Value
Baseline 3 mo Mean Change From Baseline
PT/OT No Therapy PT/OT No Therapy PT/OT No Therapy
NEADL Scaleb
Total score
No. of patients 381 381 294 304 294 304
0.5 (−0.7 to 1.7) .41
Score 50.5 (12.9) 50.9 (13.3) 49.6 (14.0) 50.3 (14.5) −1.5 (7.8) −1.0 (7.4)
Mobility
No. of patients 376 372 338 338 334 330
0.1 (−0.3 to 0.5) .56
Score 13.9 (4.0) 13.8 (4.2) 13.6 (4.2) 13.6 (4.4) −0.4 (2.6) −0.2 (2.4)
Kitchen activities
No. of patients 379 373 337 337 335 329
0.005 (−0.3 to 0.3) .97
Score 13.0 (2.7) 13.0 (2.9) 13.0 (3.0) 12.9 (3.2) −0.2 (2.2) −0.2 (1.9)
Domestic tasks
No. of patients 374 370 330 332 325 323
0.5 (−0.06 to 1.0) .08
Score 10.9 (4.2) 11.1 (4.3) 10.4 (4.5) 10.8 (4.4) −0.8 (3.4) −0.3 (3.2)
Leisure activities
No. of patients 376 365 318 329 316 318
0.01 (−0.4 to 0.4) .94
Score 12.9 (4.1) 13.0 (4.0) 13.0 (4.1) 13.1 (4.0) −0.2 (2.4) −0.1 (2.4)
PDQ-39b
No. 380 377 349 351 348 347
Mobility 32.7 (26.1) 31.3 (25.8) 33.2 (27.3) 33.3 (28.0) 1.1 (17.1) 2.6 (15.8) −1.5 (−3.9 to 1.0) .23
Activities of daily living 31.3 (23.1) 30.6 (21.8) 32.1 (23.8) 31.5 (23.8) 1.6 (14.3) 1.0 (16.7) 0.7 (−1.7 to 3.0) .58
Emotional well-being 23.9 (18.5) 23.0 (18.1) 25.9 (19.8) 25.5 (20.3) 2.6 (13.1) 3.0 (16.8) −0.5 (−2.7 to 1.8) .68
Stigma 18.3 (22.9) 17.1 (21.0) 19.8 (23.1) 17.6 (21.3) 1.6 (17.7) 0.9 (17.5) 0.7 (−2.0 to 3.3) .62
Social support 6.6 (14.0) 5.7 (11.0) 10.3 (17.4) 9.3 (15.1) 3.6 (15.6) 3.8 (14.9) −0.2 (−2.5 to 2.0) .83
Cognition 26.6 (20.1) 27.3 (21.1) 28.8 (20.6) 29.6 (21.6) 2.2 (16.5) 2.2 (17.0) −0.05 (−2.6 to 2.4) .97
Communication 16.5 (18.2) 18.5 (19.8) 20.8 (20.1) 21.8 (21.1) 4.8 (15.7) 3.0 (17.4) 1.8 (−0.7 to 4.2) .16
Bodily discomfort 34.8 (23.4) 35.9 (24.0) 36.5 (24.4) 38.6 (24.1) 2.0 (20.7) 2.8 (21.1) −0.8 (−3.9 to 2.3) .62
Summary index 23.8 (14.5) 23.7 (14.4) 25.9 (16.5) 25.9 (16.5) 2.4 (9.5) 2.4 (10.8) 0.007 (−1.5 to 1.5) .99
EQ-5Db
Quotient score
No. of patients 378 374 345 345 342 338 −0.03 (−0.07 to
−0.002) .04Score 0.64 (0.27) 0.66 (0.25) 0.65 (0.25) 0.63 (0.26) 0.002 (0.23) −0.03 (0.21)
Visual analogue score
No. of patients 376 376 346 347 341 342
−0.2 (−2.6 to 2.2) .88
Score 68.5 (17.5) 68.6 (17.0) 67.4 (18.2) 66.8 (17.8) −1.8 (17.1) −1.9 (14.3)
Abbreviations: EQ-5D, EuroQol-5D; NEADL, Nottingham Extended Activities of
Daily Living; OT, occupational therapy; PDQ-39, Parkinson Disease
Questionnaire–39; PT, physical therapy.
a To aid interpretation, regardless of scale, a positive mean difference favors no
therapy group and a negative mean difference favors the PT/OT group.
b The NEADL total score: ranges from0 to 66, where higher scores are better
and a positive change is an improvement in score. PDQ-39: ranges from0 to
100, where lower scores are better and a negative change is an improvement
in score. EQ-5D quotient: ranges from −0.59 to 1, where higher scores are
better and a positive change is an improvement in score. EQ-5D VAS: ranges
from0 to 100, where higher scores are better and a positive change is an
improvement in score.
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physiotherapists provided specific PDexercise advice accom-
paniedby abooklet, and therewasnoevidenceof a formal ex-
ercise progression protocol for any patient. Occupational
therapy assessed the full range of ADL, but predominant in-
terventions were equipment provision, onward referral, and
other advice (eg, management of sleep disorders and apply-
ing for benefits). There was little task-related practice.
OutcomeMeasures
The mean NEADL total score deteriorated from baseline to 3
monthsby 1.5points in the therapies groupcomparedwith 1.0
point in the no therapy group (difference, 0.5 points; 95% CI,
−0.7 to 1.7; P = .41; Table 2). No difference was seen in any of
the individual categories of the NEADL score (Table 2). Re-
peated-measures analysis of the NEADL across all points
showed no difference between the treatment arms (Figure 2;
eTable 1 in Supplement 2).
ThemeanPDQ-39summaryindexdeterioratedby2.4points
in both groups from baseline to 3 months (difference, 0.007
points; 95%CI, −1.5 to 1.5; P = .99; Table 2). No differencewas
seen inanyof the8domainsof thePDQ-39 (Table2). The slight
improvementof0.002points intheEQ-5Dquotient inthethera-
piesgroupbetweenbaselineand3monthscomparedwitha0.03-
pointdeteriorationinthenotherapygroupwasofborderlinesig-
nificance (difference, −0.03; 95%CI, −0.07 to−0.002;P = .04;
Table 2). Therewasnodifference in theEQ-5Dvisual analogue
score (difference, −0.2; 95%CI, −2.6 to 2.2: P = .88; Table 2).
Repeated-measures analysis over 15 months found sig-
nificant divergence inPDQ-39 summary index (curvesdiverg-
ing at 1.55 points per annum; 95% CI, 0.47-2.62; P = .005;
Figure2) and for theADL,emotionalwell being, andsocial sup-
port domains in favor of therapy (eTable 2 in Supplement 2),
but therewasnodifference in themobilitydomain. Therewas
also a borderline significant difference over time in theEQ-5D
quotient in favorof the therapies arm (0.02; 95%CI,0.00007-
0.03; P = .04; Figure 2).
Sensitivityanalysiswith imputationofmissingNEADLval-
uesdidnotchangetheresultsnordidrepeatingthePDQ-39analy-
siswithout imputationofmissingvaluesusing theexpectation
maximizationalgorithmaffect the results.Wealsoanalyzedthe
primaryoutcomeofmeanchangebetweenbaselineand3months
forNEADLtotal scoredatausinganalysisof covariance, adjust-
ing for baselineNEADL score and the otherminimization vari-
ables, but thismade no difference to the result.
Planned subgroup analyses for NEADL total score found
no evidence of difference in therapy effect at 3 months ac-
cording to baseline total NEADL score, age, or disease sever-
ity (eFigure in Supplement 2).
Fourhundredandseventy threepatients (62%)hadacare-
giver and 406 caregivers (86%) agreed to take part in the trial
(meanage,67years; 76%female).Therelationshipbetweenpa-
tient andcaregiverwasmostoftenpartneror spouse (72%).Al-
thoughtherewasnodifference incaregiverSF-12physical com-
ponent score at 3 months, there was less decline in caregiver
SF-12 mental component score (difference, −2.1; 95 CI, −3.9 to
–0.3; P = .02; Table 3) although this was not maintained with
longer follow-up (eTable 3 and eTable 4 in Supplement 2).
Adverse Events
Targeted adverse events are detailed in eTable 5 in the
Supplement2.Therewerenodifferences inadverseeventsbe-
tween trial arms at 3 or 15 months.
Discussion
ThePDREHABTrial showedthatPTandOTwerenotassociated
withclinicallymeaningful immediateormedium-termbenefi-
cial effectsonADLorQoL inmild tomoderatePD.Themedium-
Figure2.Medium-termScores inActivitiesofDaily LivingandQualityofLife
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term significant differences in QoLmeasured by PDQ-39 sum-
mary index and EQ-5D quotient in favor of therapywere small
anddidnot reachclinically significant levels,whichwedefined
as twice theminimally clinically important change levels.
OurCochranereviewofPTvsno intervention inPDshowed
that all forms of PT produced small benefits inmotor function
and ADL but no change in QoL.19 The Cochrane review of OT
foundinsufficientevidenceabouteffectiveness in2small trials,4
althoughalarge(n = 191)Dutchtrial foundthatOTimprovedself-
perceivedperformancebutnotQoL.20Theabsenceof anymo-
tor effect (PDQ-39mobility domain) or response in ADL in the
PDREHABTrial is likely to bemultifactorial owing to early dis-
easestageofmostpatients, low“dose”of intervention,and lack
of consistency in therapy assessment and intervention.
Traditionally, PT and OT have been used in the more ad-
vanced stages of PD, once imbalance and falls have devel-
oped (H&Ystage≥3).1 As a result of using theuncertaintyprin-
ciple for entry into the trial, most patients in the PD REHAB
Trial had H&Y stage less than 3 at randomization. It is pos-
sible that such mild to moderate disease may not respond to
the therapies, whereas more severe disease may respond, al-
though this remains to be established. As a consequence, the
results of the PD REHAB Trial can only be generalized to pa-
tients with mild to moderate disease.
Median therapy dose was 4 sessions of 58 minutes over
8 weeks for both therapies combined. This is low in compari-
son with the 5 PT trials in the Cochrane review (5-52 weeks
of therapy).3 In a Dutch trial of PT in PD (ParkinsonNet),21
total contact time (over 6 months) between patients and
physiotherapists was 15 sessions of 30 minutes, nearly
double that in the PD REHAB Trial, but the study also
showed no evidence in favor of therapy. Importantly, the
dose delivered in the PD REHAB Trial reflects routine NHS
practice.
Table 3. Caregiver Quality of Life Scores
Scale
Mean (SD)
Mean Difference
(95% CI)a P Value
Baseline 3 mo Mean Change From Baseline
PT/OT No Therapy PT/OT No Therapy PT/OT No Therapy
SF-12b
Physical functioning
No. of patients 171 181 169 181 151 156
−5.6 (−11.0 to −0.2) .04
Score 70.3 (35.4) 76.0 (30.5) 68.6 (35.8) 70.3 (30.0) −0.7 (24.8) −6.3 (23.0)
Role physical
No. of patients 173 183 169 185 155 163
−0.5 (−5.3 to 4.3) .84
Score 75.4 (28.5) 76.7 (26.8) 69.8 (28.8) 71.0 (27.1) −5.4 (19.6) −5.9 (23.8)
Role emotional
No. of patients 172 182 170 183 155 162
−4.4 (−9.0 to 0.2) .06
Score 83.6 (23.1) 81.9 (22.9) 80.4 (24.2) 76.4 (24.9) −1.7 (20.0) −6.1 (21.5)
Social functioning
No. of patients 175 186 171 189 157 169
−3.8 (−8.9 to 1.3) .14
Score 84.9 (22.9) 83.3 (23.6) 81.0 (24.5) 78.3 (26.9) −2.9 (21.9) −6.7 (24.5)
Mental health
No. of patients 174 183 170 188 156 167
−4.3 (−8.2 to −0.4) .03
Score 68.8 (21.1) 68.6 (18.5) 67.6 (20.2) 64.6 (21.9) −0.2 (16.7) −4.5 (18.9)
Vitality
No. of patients 175 184 170 188 156 167
−4.6 (−9.2 to 0.05) .05
Score 57.4 (25.6) 61.8 (22.6) 53.8 (25.9) 53.2 (24.5) −3.5 (21.0) −8.1 (21.1)
Bodily pain
No. of patients 173 184 170 189 156 168
2.9 (−2.2 to 7.9) .27
Score 77.7 (29.3) 76.4 (28.7) 74.1 (28.8) 74.2 (28.5) −4.6 (25.0) −1.8 (21.1)
General health
No. of patients 174 186 170 190 155 170
−0.9 (−5.0 to 3.3) .68
Score 64.2 (25.3) 65.6 (26.1) 58.9 (26.0) 61.0 (25.3) −4.4 (18.6) −5.3 (19.5)
Component score
Physical
No. of patients 166 171 165 174 146 144
−0.6 (−2.3 to 1.2) .53
Score 47.1 (12.5) 48.2 (11.4) 45.1 (13.3) 46.4 (11.6) −1.6 (7.5) −2.1 (7.5)
Mental
No. of patients 166 171 165 174 146 144
−2.1 (−3.9 to −0.3) .02
Score 51.1 (10.2) 50.1 (8.9) 49.7 (10.2) 48.0 (10.5) −0.5 (7.6) −2.6 (7.9)
Abbreviations: OT, occupational therapy; PT, physical therapy; SF-12, Short
Form–12.
a To aid interpretation, regardless of scale, a positive mean difference favors no
therapy group and a negative mean difference favors PT/OT group.
b SF-12: ranges from0 to 100where higher scores are better and a positive
change is an improvement in score.
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Therapyexpert groups recommendedan individual “goal-
setting” approach for PDREHAB interventions because this is
the gold standard and addresses the personalized needs and
wishesof the individual. Therapy contentwas inkeepingwith
NHS and European guidelines on PT and OT.8-11 However, an
individualizedgoal-settingapproachwith this contentmaynot
be transferable to patientswithmild disease. The lack of task-
related practice is of particular concern because this has been
showntobea significant factor in stroke rehabilitation trials.22
We were also concerned by the low prescription and dose of
exercise in the PD REHAB Trial.
The possibility that patients with more severe disease
might showabetter responsewas examined in aplanned sub-
group analysis examining response according to baseline
NEADL score and H&Y stage. While the data did not support
this hypothesis, the numberswith severe diseasewere small,
so this is likely to be underpowered. Similarly, older patients
might respond better to the therapies because of greater lev-
els of frailty and comorbidities, but there was no evidence of
this in the subgroup analysis.
Thefidelityof the interventionwasreasonable inbotharms
of this pragmatic real-world trial. In the therapies arm, 93%of
patients (n = 353) received therapies within 3 months of ran-
domization. Whereas, only 2% (n = 9) of the no therapy arm
crossedover to receive treatmentwithin3months,mainlyow-
ing to motor progression. It is unlikely that these small pro-
portions of crossovers led to the lack of effect seen in the trial.
Despite all patients reporting ADL problems at baseline,
many hadmild disease. A total of 29% (n = 221) had a NEADL
scoreatbaselineofgreater than61and14%(n = 107)hadascore
of 65 or greater (mean baseline score, 51). This may have led
to a floor effect because the NEADL score could not improve
much from a good baseline score. However, planned sub-
group analysis showed that there was still no response in pa-
tientswithmore severe baselineNEADL scores. It should also
be noted that the NEADL results are supported by the lack of
a clinically meaningful effect on PDQ-39 ADL domain.
Conclusions
PhysiotherapyandOTusinganindividualgoal-settingapproach
producednoclinicallymeaningful short-ormedium-termben-
efits inADLorQoLinpatientswithmildtomoderatePD.Thisevi-
dencedoesnotsupporttheuseof low-dose,goal-directedPTand
OT inpatients in the early stages of PD. Future research should
explore thedevelopmentandtestingofmorestructuredand in-
tensive PT programs in patientswith all stages of PD.
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